PFE241220C18000
- 7.70
- 0.000.00%
Pfizer Newsroom
Express News | U.S. FDA: Sees Dextrose 50% Injection, 25 G/50 Ml (Ndc 0409-7517-16) Estimated Availability Recovery in March 2025
Express News | U.S. FDA: Hospira's Dextrose 50% Injection Currently in Shortage - Website
A Quick Look at Today's Ratings for Pfizer(PFE.US), With a Forecast Between $29 to $33
Anokion Announces the Early Completion of Enrollment in the ACeD-it Phase 2 and the SynCeD Phase 2a Trials of KAN-101 for the Treatment of Celiac Disease
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?
Healthcare Stocks Had a Dismal Year. Therein Lies -2-
Pfizer Options Spot-On: On December 18th, 119.73K Contracts Were Traded, With 3.76 Million Open Interest
Tesla, Bitcoin, S&P 500, Dow, Tank: Thanks a Lot FOMC | Wall Street Today
Express News | FOMC Cuts Interest Rates by 25 Basis Points, Sees Fewer Reductions Next Year
California Gov. Newsom Declares State of Emergency Over Bird Flu
Pfizer 2025 Guidance Signals Relief to Investors, UBS Says
Jim Cramer's Take on Pfizer (PFE): Can CEO Dr. Bourla's Bold Strategy Overcome Debt and Turn the Stock Around?
Express News | U.S. Supreme Court Agrees To Hear South Carolina's Bid To End Public Funding Of Abortion Provider Planned Parenthood
Dow Breaks Downward Spiral, with FOMC Rate Cut on Deck | Live Stock
Merck-Hansoh Deal for Oral GLP-1 Hurts Obesity Drug Developers
Pfizer Price Target Cut to $32.00/Share From $36.00 by Truist Securities
Pfizer Analyst Ratings
Pfizer Stock Up 5% as 2025 Guidance Meets Investor Expectations
Daily short sale tracking: NVIDIA's short volume increased by 5 million, with a short sale ratio of 10%
Promising Data for Treating Gastrointestinal Cancer Leading to Hopeful Advancements for Pancreatic & Anal Cancers